Oncoptpeptides - Bring hope through science

Bringing hope through science

Presentation of the Year-end Report 2022

Oncopeptides published its report for the fourth quarter and the 2022 year-end report on February 16, and hosted a webcast on the same day. The event was hosted by CEO Monica Shaw, together with CFO Holger Lembrér and CSO Jakob Lindberg. The presentations was held in English.

Link to the webcast and more information


Year-end report 2022

"Pepaxti represents true innovation and an improved clinical experience that benefit patients"

CEO Monica Shaw


See the Webcast                     

For further information, please contact:

Rolf Gulliksen
Global Head of Corporate Communications


Q1 report May 4, 2023

Profile image

Press release -

Oncopeptides receives a research grant from Sweden´s Innovation Agency to explore the PDC platform in solid tumors

Read press release
Events Oncopeptides

Upcoming events

View calendar

Monica Shaw CEO Oncopeptides

Monica Shaw appointed CEO

On January 4, 2023, Oncopeptides announced that the Board of Directors has appointed Dr Monica Shaw as Chief Executive Officer, CEO, of Oncopeptides. She replaces Jakob Lindberg, who has been the CEO since November 15, 2021. Lindberg assumes his previous position as Chief Scientific Officer. These changes are effective immediately.

Read the press release

Jakob Lindberg interviewed by Di.TV

Jakob Lindberg interviewed by Di.TV regarding the leadership change

On Wednesday January 4, Jakob Lindberg was interviewed by by the Swedish economy TV channel Di.TV regarding the announced leadership change in Oncopeptides. Jakob Lindberg comments on his resignation as CEO of Oncopeptides and the appointment as Chief Scientific Officer.

See the interview on Di.TV (in Swedish)

Jakob Lindberg, CEO Oncopeptides.com

CEO Jakob Lindberg interviewed by Di.TV regarding the Q3 report and the EU and US market

On November 9, 2022, CEO Jakob Lindberg was interviewed by Börsmorgon in the Swedish Dagens Industri Di.TV regarding the Q3 report and the EU and US market. See the interview by clicking the link below. The interview is in Swedish.

To the interview in Di.TV

Tyska lanseringen av Pepaxti - presentation

Fredagen den 21 oktober kl.14.00, 2022, håller Oncopeptides en presskonferens för att prata om den tyska lanseringen av Pepaxti®.

Se presentationen i PDF här

Jakob Lindberg

European Commission approves Oncopeptides' Pepaxti

“The approval of Pepaxti in Europe is foundational for Oncopeptides, and brings excellent news for patients and shareholders,” says Jakob. “Despite the introduction of novel therapies, patients with triple class refractory disease have a high unmet medical need, since their treatment options ultimately become exhausted.”

Link to the press release

Webcast - CHMP issues a positive opinion recommending full approval of Oncopeptides Pepaxti in EU

June 23, 2022, the European Medicines Agency´s (EMA) Committee for Medicinal Products for Human Use (CHMP), has unanimously adopted a positive opinion recommending a full marketing authorization approval (MAA) of Pepaxti® (melphalan flufenamide, also called melflufen) in EU. 

Investors, financial analysts, and media were invited to participate in a webcast with a Q&A session on June 27, 2022, at 11:00 (CET). The event was hosted by CEO Jakob Lindberg, CMO Klaas Bakker and CFO Annika Muskantor. 

More info, presentation and the webcast link

Oncopeptides vision

Vision of Oncopeptides

“Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”

Cultures & Values

We are a science driven, entrepreneurial company, committed to bringing innovation to patients with an unmet medical need, and improving their lives.

Read more


Annual Report 2021

Letter from the CEO - Science is leading the way


For further information, please contact:

Rolf Gulliksen
Global Head of Corporate Communications

Profile image

Journey of innovation

Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden's leading cancer researchers and cancer research institutions. 
Read more

Oncopeptides via e-mail